Treatment for Elevated Apolipoprotein B (apo B) Levels

Understanding Apolipoprotein B

Apolipoprotein B (apo B) is the major apolipoprotein of all atherogenic lipoproteins including VLDL, IDL, and LDL particles, according to the European Heart Journal 1
Elevated apo B levels have strong predictive power for severity of coronary atherosclerosis and coronary heart disease events, as reported by Circulation and the Journal of the American College of Cardiology 2, 3

For patients at very high cardiovascular risk, the European Heart Journal and Mayo Clinic Proceedings recommend an apo B target <80 mg/dL 4, 5
For patients at high cardiovascular risk, the European Heart Journal and Mayo Clinic Proceedings recommend an apo B target <100 mg/dL 4, 5
When apo B measurement is not available, non-HDL cholesterol can serve as an acceptable surrogate marker, according to Circulation and the Journal of the American College of Cardiology 2, 3

The American Heart Association recommends reducing saturated fat to <7% of total daily calories, limiting dietary cholesterol to <200 mg/day, and reducing simple carbohydrate intake to help lower triglycerides, as summarized by Circulation 2, 3
Increasing physical activity to at least 30 minutes of moderate-intensity exercise most days of the week is recommended, as reported by the European Heart Journal 1
Weight reduction for those with excess weight or obesity is recommended, according to Circulation and the Journal of the American College of Cardiology 2, 3

The American College of Cardiology recommends initiating high-intensity statin therapy for patients at very high cardiovascular risk, as reported by Mayo Clinic Proceedings 5, 6
Moderate-intensity statin therapy is recommended for those at high cardiovascular risk, according to Mayo Clinic Proceedings 5, 6

The American College of Cardiology recommends adding ezetimibe 10 mg daily if target apo B levels are not achieved with maximally tolerated statin therapy, as reported by Mayo Clinic Proceedings 5, 6

For patients with persistently elevated apo B despite statin and ezetimibe, the American College of Cardiology recommends considering PCSK9 inhibitors for very high-risk patients, as reported by Mayo Clinic Proceedings 5, 6
For patients with elevated triglycerides, the American Heart Association recommends considering fibrates or nicotinic acid, according to Circulation 2, 7

The American Diabetes Association recommends more aggressive apo B targets for patients with diabetes, as reported by Mayo Clinic Proceedings 5, 6
Optimizing glycemic control is recommended as part of the treatment strategy, according to the American Diabetes Association, as summarized by Circulation 2, 3

The American Heart Association recommends that when triglycerides are ≥200 mg/dL, non-HDL cholesterol goal should be 30 mg/dL higher than the LDL cholesterol goal, as reported by Circulation 2, 3
For triglycerides >500 mg/dL, immediate treatment with fibrates or nicotinic acid is recommended to prevent pancreatitis, according to the American Heart Association, as summarized by Circulation 2, 3

The American College of Cardiology recommends measuring apo B levels 6-12 weeks after initiating or changing therapy, as reported by Mayo Clinic Proceedings 5, 6
If apo B measurement is unavailable, non-HDL cholesterol can be used as a surrogate, according to Circulation and the Journal of the American College of Cardiology 2, 3

The American College of Cardiology recommends initiating high‑intensity statin therapy (atorvastatin 40–80 mg daily or rosuvastatin 20–40 mg daily) in very high‑risk adults (e.g., established ASCVD, diabetes with target‑organ damage, severe CKD) to achieve ≥50 % reduction in LDL‑C 8.
The American College of Cardiology advises adding a PCSK9‑inhibitor for very high‑risk patients who remain above their apoB target after maximally tolerated statin (± ezetimibe) therapy 8.

When apoB measurement is unavailable, the American College of Cardiology recommends using non‑HDL cholesterol (total cholesterol − HDL‑C) as a surrogate, aiming for a level that is 30 mg/dL higher than the LDL‑C goal 8.

For patients with triglycerides ≥200 mg/dL, the American College of Cardiology suggests considering fibrates or nicotinic acid, with the non‑HDL cholesterol target set 30 mg/dL above the LDL‑C goal 8.